Agenus, Inc. – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 11 PAGES: 73

The report provides data on the Agenus, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Agenus, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Agenus, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									              Agenus, Inc. – Product Pipeline Review – 2012


                                                                                          Reference Code: GMDHC02188CDB
                                                                                                 Publication Date: MAY 2012




Agenus, Inc. – Product Pipeline Review – 2012                                             GMDHC02188CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Agenus, Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
Agenus, Inc. Snapshot ....................................................................................................................................................................... 6
    Agenus, Inc. Overview................................................................................................................................................................... 6
    Key Information ............................................................................................................................................................................. 6
    Key Facts....................................................................................................................................................................................... 6
Agenus, Inc. – Research and Development Overview ....................................................................................................................... 7
    Key Therapeutic Areas .................................................................................................................................................................. 7
Agenus, Inc. – Pipeline Review .......................................................................................................................................................... 9
    Pipeline Products by Stage of Development ................................................................................................................................. 9
    Pipeline Products – Monotherapy ............................................................................................................................................... 10
Agenus, Inc. – Pipeline Products Glance ......................................................................................................................................... 11
    Agenus, Inc. Clinical Stage Pipeline Products ............................................................................................................................. 11
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 11
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 12
Agenus, Inc. – Drug Profiles ............................................................................................................................................................. 13
    HerpV .......................................................................................................................................................................................... 13
        Product Description................................................................................................................................................................. 13
        Mechanism of Action ............................................................................................................................................................... 13
        R&D Progress ......................................................................................................................................................................... 13
    Nystatin ....................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    Prophage ..................................................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
Agenus, Inc. – Pipeline Analysis ...................................................................................................................................................... 17
    Agenus, Inc. – Pipeline Products by Therapeutic Class .............................................................................................................. 17
    Agenus, Inc. – Pipeline Products By Target ................................................................................................................................ 18
    Agenus, Inc. – Pipeline Products by Route of Administration ...................................................................................................... 19
    Agenus, Inc. – Pipeline Products By Mechanism of Action ......................................................................................................... 20
Agenus, Inc. – Recent Pipeline Updates ......................................................................................................................................... 21
Agenus, Inc. - Dormant Projects....................................................................................................................................................... 25
Agenus, Inc. - Discontinued Pipeline Products ................................................................................................................................. 26
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 26
        Aroplatin .................................................................................................................................................................................. 26
        ATRA-IV .................................................................................................................................................................................. 26
        AU-801 .................................................................................................................................................................................... 27
        HSPPC-70 .............................................................................................................................................................................. 27



Agenus, Inc. – Product Pipeline Review – 2012                                                                                            GMDHC02188CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                       Page(2)
Agenus, Inc. – Product Pipeline Review




         Zintevir .................................................................................................................................................................................... 27
Agenus, Inc. – Company Statement ................................................................................................................................................. 28
Agenus, Inc. – Locations And Subsidiaries ...................................................................................................................................... 31
    Head Office.................................................................................................................................................................................. 31
Agenus, Inc., Recent Developments ................................................................................................................................................ 32
    Agenus, Inc.- Press Release ....................................................................................................................................................... 32
         Apr 17, 2012: Agenus Presents New Phase II Data From Brain Cancer Study Of Prophage Vaccine At Plenary Session Of
         AANS ...................................................................................................................................................................................... 32
         Apr 17, 2012: NCI Group Selects HSPPC-96 Vaccine For Randomized Large-Scale Study With Bevacizumab For Recurrent
         Glioblastoma ........................................................................................................................................................................... 32
         Apr 02, 2012: Agenus's Phase II Study Of Brain Cancer Vaccine To Be Presented At 80th AANS Annual Scientific Meeting
         ................................................................................................................................................................................................ 33
         Aug 12, 2009: Antigenics Begins Enrollment Of Patients In Its Phase II Trial Of Oncophage Cancer Vaccine In Newly
         Diagnosed Glioma .................................................................................................................................................................. 34
         Jun 01, 2009: Antigenics Presents Positive Oncophage Interim Survival Data At ASCO ....................................................... 34
         Mar 12, 2009: Antigenics Receives European Orphan Drug Designation For Oncophage Cancer Vaccine In Brain Cancer . 35
Financial Deals Landscape .............................................................................................................................................................. 37
    Agenus, Inc., Deals Summary ..................................................................................................................................................... 37
Agenus, Inc., Pharmaceuticals & Healthcare, Deal Details .............................................................................................................. 39
    Partnerships ................................................................................................................................................................................ 39
         Agenus Enters Into Research Agreement With Memorial Sloan-Kettering Cancer Center ..................................................... 39
    Licensing Agreements ................................................................................................................................................................. 41
         Agenus Amends Licensing Agreement With GlaxoSmithKline For QS-21 Stimulon ............................................................... 41
         Agenus Enters Into Licensing And Development Agreement With NewVac For Oncophage ................................................. 43
         Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For QS-21 Stimulon .......................................... 44
         Antigenics Enters Into Licensing Agreement With Johnson & Johnson .................................................................................. 46
         GlaxoSmithKline Expands Licensing Agreement With Antigenics .......................................................................................... 47
         Antigenics Enters Into Licensing Agreement With Pharmexa ................................................................................................. 48
    Equity Offering ............................................................................................................................................................................. 49
         Agenus Files Registration Statement For Private Placement Of Up To 5 Million Shares........................................................ 49
         Agenus Completes Public Offering Of Common Stock For $7 Million..................................................................................... 50
         Antigenics Files Shelf Registration Statement For Private Placement .................................................................................... 52
         Antigenics Completes Public Offering Of $8.5 Million ............................................................................................................. 54
         Antigenics Completes Private Placement Of $10 Million ........................................................................................................ 56
         Antigenics 
								
To top